Skip to content
‹ Back to IndustriesHealthcare

New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc has bought Sohar Health, its first acquisition in nearly 20 years. Sohar's software finds and verifies a patient's insurance coverage from a name and birth date. Zocdoc wants that check to work across its Care Access Network, which lets insurers, consumer apps and AI tools embed Zocdoc's clinician search and scheduling on their own websites and apps.

  • 01After nearly 20 years without an acquisition, Zocdoc's first purchase is the insurance check that sits between a patient's search and a booked appointment.
  • 02For practices that pay Zocdoc per booking, the sharper question is how often coverage verified at booking matches what the front desk confirms at check-in.

Oct 24, 2026

The physical exam splits into parts, and each goes remote at its own pace

The physical exam splits into parts, and each goes remote at its own pace

One weak link in virtual physical exams is patient technique, since home readings depend on how patients take them.

  • 01Charting what a patient could not do for lack of home equipment is part of the exam record, and federal telehealth guidance ties that documentation to coding and billing.
  • 02Remote exams fit best where home data already accumulates: a week of home blood pressure readings or continuous glucose data shows what a single office reading cannot.

Oct 21, 2026

Healthcare staff judge leadership values by decisions, not statements

Healthcare leaders are judged by their actions and accessibility, not their stated values. Dr. David Schreiner argues that a leader’s legacy rests mostly on how people experienced working for them, while still recognizing financial performance matters. He also urges clearer priorities, visible leadership presence, and stronger succession planning.

  • 01Healthcare employees assess leadership values primarily through decisions made rather than statements.
  • 02Trust in leadership is gained when there is alignment between stated values and actual organizational decisions.

Oct 20, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512